Pulmatrix Mulls Divestment Of Clinical Assets, Proprietary iSPERSE Technology As Part Of Proposed Merger With Cullgen
Benzinga Newsdesk 1 year ago
News
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule drugs to the
As part of the proposed merger, Pulmatrix currently intends to divest its assets including its proprietary dry powder delivery technology, iSPERSE™, which enables delivery of small- or large-molecule drugs to the lungs by inhalation to treat migraine and respiratory diseases
Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ Technology